公开(公告)号：US09795587B2

公开(公告)日：2017-10-24

申请号：US14575387

申请日：2014-12-18

申请人： Cornell Research Foundation, Inc.

发明人： Rajiv R. Ratan ,  Ambreena Siddiq ,  Juan Chavez

IPC分类号： A61K31/352 ,  A61K31/343 ,  A61K31/24 ,  A61K31/58

CPC分类号： A61K31/352 ,  A61K31/24 ,  A61K31/343 ,  A61K31/58

摘要： The present invention relates to methods for enhancing Hypoxia inducible factor-1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 3,6-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride, 2,8-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate, tilorone analog R-9536-DA, indoprofen, ciclopiroxolamine, tryptophan, ansindione, nabumetone, oxybendazole, albendazole, tropicamide, pramoxine hydrochloride, atenolol, mebendazole, carbetapentane citrate, monensin sodium, methoxyvone, hydroxyzine, phenazopyridine, clofoctol, ipraflavone, zomepirac, biochanin A, xylometazoline hydrochloride, fenbendazole, pirenzepine, triprolidine hydrochloride, daidzein, tripelennamine citrate, colchicines, aminopyridine, trimethoprim, helenine, hydroxyurea, amiodarone hydrochloride, clindamycin hydrochloride, sulfachlorpyridazine, mephenesin, semustine, clofivric acid, clofibrate, ibuprofen, hyoscyamime, nafcillin sodium, piperin, clidinium bromide, trioxsalen, hydralazine and HIF alpha protein fused to a carrier peptide.

公开(公告)号：US20150258058A1

公开(公告)日：2015-09-17

申请号：US14575387

申请日：2014-12-18

申请人： Cornell Research Foundation, Inc.

发明人： Rajiv R. Ratan ,  Ambreena Siddiq ,  Juan Chavez

IPC分类号： A61K31/352 ,  A61K31/343 ,  A61K31/24

CPC分类号： A61K31/352 ,  A61K31/24 ,  A61K31/343 ,  A61K31/58

摘要： The present invention relates to methods for enhancing Hypoxia inducible factor-1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 3,6-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride, 2,8-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate, tilorone analogue R-9536-DA, indoprofen, ciclopiroxolamine, tryptophan, ansindione, nabumetone, oxybendazole, albendazole, tropicamide, pramoxine hydrochloride, atenolol, mebendazole, carbetapentane citrate, monensin sodium, methoxyvone, hydroxyzine, phenazopyridine, clofoctol, ipraflavone, zomepirac, biochanin A, xylometazoline hydrochloride, fenbendazole, pirenzepine, triprolidine hydrochloride, daidzein, tripelennamine citrate, colchicines, aminopyridine, trimethoprim, helenine, hydroxyurea, amiodarone hydrochloride, clindamycin hydrochloride, sulfachlorpyridazine, mephenesin, semustine, clofivric acid, clofibrate, ibuprofen, hyoscyamime, nafcillin sodium, piperin, clidinium bromide, trioxsalen, hydralazine and HIF alpha protein fused to a carrier peptide.

摘要翻译： 本发明涉及通过使细胞与以下任一化合物接触来增强细胞中缺氧诱导因子-1（HIF）活性的方法：3,6-双[2-（二甲基氨基）乙氧基] -9h-呫吨 - 9-二氢二氢氯化物，2,8-双[二甲基氨基乙酰基]二苯并呋喃二盐酸盐水合物，十二酮类似物R-9536-DA，吲哚洛芬，环吡酮，色氨酸，苯二酮，萘丁酮，苯苯达唑，阿苯哒唑，托吡卡胺，盐酸普拉莫辛，阿替洛尔，甲苯咪唑， 莫能菌素钠，甲氧基雄酮，羟基嗪，苯扎氮吡啶，clochanctol，异丙嗪，替沙星，鹰嘴豆烯A，甲基咪唑啉盐酸盐，芬苯达唑，哌仑西平，盐酸曲洛他啶，黄豆苷元，柠檬酸泰伦仑，秋水仙素，氨基吡啶，甲氧苄啶，海洛因，羟基脲，盐酸胺碘酮，盐酸克林霉素， ，米芬舍辛，西司他丁，氯比酸，氯贝丁酯，布洛芬，莨菪素，萘芬西林钠，胡椒素，溴化钡，t rioxsalen，肼屈嗪和与载体肽融合的HIFα蛋白。